GlassScriptPhysician profile
Frank C Wade
NPI 1619934940
$1,973.46
in general payments reported to CMS, 2019-2025
23 companies · $266 in 2025
The $266 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $660 · 2021: $183 · 2022: $169 · 2023: $81.34 · 2024: $271 · 2025: $266.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $618.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.10 | 2019-2025 | Jardiance, Ofev |
| Novo Nordisk INC | $314.24 | 2019-2023 | Ozempic, Rybelsus |
| Abbvie INC. | $273.89 | 2020-2025 | Vraylar |
| Lilly USA, LLC | $233.43 | 2019-2024 | Mounjaro |
| Astellas Pharma US INC | $95.49 | 2019-2021 | |
| Allergan, INC. | $81.42 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $79.24 | 2019-2024 | Farxiga |
| Amgen INC. | $70.25 | 2019 | |
| Merck Sharp & Dohme LLC | $66.48 | 2019-2020 | |
| Glaxosmithkline, LLC. | $66.29 | 2019-2025 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $66.11 | 2021-2024 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $48.20 | 2024 | Rexulti |
| Eisai INC. | $41.52 | 2020 | |
| Vanda Pharmaceuticals INC. | $35.85 | 2024 | Fanapt |
| Sanofi-Aventis U.S. LLC | $34.79 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.84 | 2019 | |
| Avanir Pharmaceuticals, INC. | $25.62 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $18.74 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.10 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.22 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.28 | 2025 | Caplyta |
| Inari Medical, INC. | $14.17 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Axsome Therapeutics, INC. | $13.19 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.